Dose Escalation Study to Evaluate the Safety and Antiviral Activity of Val-mCyd in Adults With Chronic Hepatitis C
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 65 Years (Adult)
Sexes Eligible for Study:
Documented clinical history of chronic hepatitis C and compensated liver disease
No antiviral treatment for hepatitis C in the 6 months prior to the Screening visit
Other protocol-defined inclusion criteria may apply.
Patient is pregnant or breastfeeding
Patient is co-infected with HBV or HIV
Other protocol-defined exclusion criteria may apply.